Jump to content
RemedySpot.com

Placebos without Deception

Rate this topic


Recommended Posts

Posted

The below may be of interest:

Placebos without Deception: A Randomized Controlled Trial in Irritable Bowel

Syndrome

http://www.plosone.org/article/info:doi/10.1371/journal.pone.0015591

Placebo treatment can significantly influence subjective symptoms. However, it

is widely believed that response to placebo requires concealment or deception.

We tested whether open-label placebo (non-deceptive and non-concealed

administration) is superior to a no-treatment control with matched

patient-provider interactions in the treatment of irritable bowel syndrome

(IBS).

Two-group, randomized, controlled three week trial (August 2009-April 2010)

conducted at a single academic center, involving 80 primarily female (70%)

patients, mean age 47¡À18 with IBS diagnosed by Rome III criteria and with a

score ¡Ý150 on the IBS Symptom Severity Scale (IBS-SSS). Patients were

randomized to either open-label placebo pills presented as ¡°placebo pills made

of an inert substance, like sugar pills, that have been shown in clinical

studies to produce significant improvement in IBS symptoms through mind-body

self-healing processes¡± or no-treatment controls with the same quality of

interaction with providers. The primary outcome was IBS Global Improvement Scale

(IBS-GIS). Secondary measures were IBS Symptom Severity Scale (IBS-SSS), IBS

Adequate Relief (IBS-AR) and IBS Quality of Life (IBS-QoL).

Open-label placebo produced significantly higher mean (¡ÀSD) global improvement

scores (IBS-GIS) at both 11-day midpoint (5.2¡À1.0 vs. 4.0¡À1.1, p<.001) and at

21-day endpoint (5.0¡À1.5 vs. 3.9¡À1.3, p & #8202;= & #8202;.002). Significant

results were also observed at both time points for reduced symptom severity

(IBS-SSS, p & #8202;= & #8202;.008 and p & #8202;= & #8202;.03) and adequate relief

(IBS-AR, p & #8202;= & #8202;.02 and p & #8202;= & #8202;.03); and a trend favoring

open-label placebo was observed for quality of life (IBS-QoL) at the 21-day

endpoint (p & #8202;= & #8202;.08).

Placebos administered without deception may be an effective treatment for IBS.

Further research is warranted in IBS, and perhaps other conditions, to elucidate

whether physicians can benefit patients using placebos consistent with informed

consent.

=============

Carruthers

Wakefield, UK

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
×
  • Create New...